Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Minimal residual disease status after inotuzumab ozogamicin in patients with relapsed/refractory acute lymphoblastic leukemia

Posted by on Jan 7, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if minimal residual disease negativity is useful as a prognostic factor after inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia.   This study concluded minimal residual negativity with complete remission is associated with a better...

Read More

Which factors affect the safety and effectiveness of imatinib treatment for newly diagnosed chronic myeloid leukemia?

Posted by on Jan 7, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of imatinib treatment in patients with newly diagnosed chronic myeloid leukemia. This study concluded that patients of lower weight and older age are more vulnerable to side effects.  Some background Imatinib (Gleevec) is a targeted therapy...

Read More

The treatment of standard-risk B-cell acute lymphoblastic leukemia with intensified postinduction therapy

Posted by on Dec 29, 2019 in Leukemia | 0 comments

In a nutshell This study evaluated if the intensified postinduction therapy is safe and effective to treat children with standard-risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study concluded that the treatment excellently impacted survival among patients, but further intensifying the therapy might be unnecessary. Some background B-ALL is...

Read More

Managing advanced phase chronic myeloid leukemia

Posted by on Dec 24, 2019 in Leukemia | 0 comments

In a nutshell This study reviewed treatment options for advanced phase chronic myeloid leukemia. This study concluded that managing advanced phase chronic myeloid leukemia remains challenging and treatment options include tyrosine kinase inhibitors, chemotherapy, and transplant.  Some background Chronic myeloid leukemia (CML) can be...

Read More

Comparing new-generation tyrosine kinase inhibitors and imatinib in patients with newly diagnosed chronic myeloid leukemia

Posted by on Dec 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to compare the effectiveness of new-generation tyrosine kinase inhibitors and imatinib in patients with newly diagnosed chronic myeloid leukemia.  This study concluded that for first-line treatment, new-generation tyrosine kinase inhibitors are better than imatinib.  Some background Tyrosine...

Read More

Searching for patients with relapsed or unresponsive chronic lymphocytic leukemia to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Leukemia | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH,...

Read More

Are the currently prescribed doses of tyrosine kinase inhibitors too high for elderly patients with chronic myeloid leukemia?

Posted by on Dec 15, 2019 in Leukemia | 0 comments

In a nutshell This study investigated the prescribed doses of tyrosine kinase inhibitors (TKIs) and the outcomes of elderly patients with chronic myeloid leukemia (CML). The study concluded that the currently prescribed TKI dose might be higher than necessary in elderly patients. Some background TKIs such as imatinib (Glivec), dasatinib...

Read More